Literature DB >> 34387536

SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?

Paulus S Rommer1, Gabriel Bsteh1, Thomas Berger1, Uwe Klaus Zettl1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34387536     DOI： 10.1177/13524585211039128

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  4 in total

1.  T cells step up after SARS-CoV-2 vaccination with B cell depletion.

Authors:  Thomas Berger; Barbara Kornek
Journal:  Nat Rev Neurol       Date:  2021-12       Impact factor: 42.937

Review 2.  Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.

Authors:  Grace Y Gombolay; Monideep Dutt; William Tyor
Journal:  Ann Clin Transl Neurol       Date:  2022-07-19       Impact factor: 5.430

3.  SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.

Authors:  Masoud Etemadifar; Nahad Sedaghat; Hosein Nouri; Noushin Lotfi; Ahmad Chitsaz; Reza Khorvash; Hamed Zolfaghari; Alireza Ghasemi Movaghar; Mohammad Pourabbas; Mehri Salari
Journal:  Mult Scler Relat Disord       Date:  2021-11-22       Impact factor: 4.808

4.  Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.

Authors:  Gabriel Bsteh; Harald Hegen; Gerhard Traxler; Nik Krajnc; Fritz Leutmezer; Franziska Di Pauli; Barbara Kornek; Paulus Rommer; Gudrun Zulehner; Sophie Dürauer; Angelika Bauer; Sarah Kratzwald; Sigrid Klotz; Michael Winklehner; Florian Deisenhammer; Michael Guger; Romana Höftberger; Thomas Berger
Journal:  Eur J Neurol       Date:  2022-02-09       Impact factor: 6.288
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.